Everolimus-Eluting Platinum Chromium Coronary Stent System
Freedom From Long-term Polymer Exposure
Professors Ian Meredith, Adrian Banning and Tan Huay Cheem provide their commentary about the SYNERGY stent platform, and the recently reported data from the EVOLVE Trial 4-Year and EVOLVE II Trial Diabetes Substudy 12 month presentations. In addition, they also provide their analysis of the increasing evidence of how the SYNERGY stent may lead to optimal healing and reducing the risk of neoathersclerosis.
Synchronous Drug Elution and Polymer Absorption
Exceptional Safety and Performance
Four-Year Results: 0% ARC Definite/Probable ST and 1.1% TLR at Four Years1
EVOLVE II Diabetes Substudy
12-Month Clinical Results
EVOLVE II DM Clinical Trial. Presented by Stephan Windecker, MD at PCR 2015
^Cutlip et al, Circulation. 2007; 115(17):2344;
* Spontaneous MI was defined as the rise and/or fall of cardiac biomarkers with ≥1 value >99th percentile of the upper reference limit (URL) with ≥1 of the following: symptoms of ischemia, ECG changes, and or evidence of loss of myocardium. Peri-PCI MI was defined by any of the following: i) CK-MB >3X URL within 48 hours, ii) new pathological Q waves, iii) autopsy evidence. All ST were definite.